rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ENSC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Ensysce Biosciences at UBS biopharma conference: pain bet takes shape
      Nov 17Investing.comENSCUBS
      Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business Highlights
      Nov 12Yahoo FinanceENSC
      UBS initiates Ensysce Biosciences stock with buy on pain therapy potential
      Nov 12Investing.comENSCUBS
      Ensysce Biosciences announces executive leadership changes after annual meeting
      Nov 4Investing.comENSC
      Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai

      ~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing innovative neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome ("CRPS") today announced that James Morrison, President of , participated in the Family Office Summit, Dubai, on Octo

      Oct 21Yahoo FinanceENSC
      Ensysce submits Phase 2a protocol for CRPS treatment CY200
      Sep 24Investing.comENSC
      Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
      Sep 24Yahoo FinanceENSC
      Ensysce hosts symposium at PainWeek, attends FDA hearing
      Sep 15Investing.comENSC
      Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
      Sep 15Yahoo FinanceENSC
      Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

      SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.

      Sep 14Yahoo FinanceENSC
      Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

      SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.

      Sep 2Yahoo FinanceENSC
      Ensysce completes enrollment in opioid overdose study
      Aug 31Investing.comENSC
      Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period

      Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailENSC

      This is the newest page. Registered accounts read further back.